Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Opin Pharmacol ; 53: 55-65, 2020 08.
Article in English | MEDLINE | ID: mdl-32599447

ABSTRACT

Liver X receptors (LXRs) are transcription factors from the nuclear receptor family that can be pharmacologically activated by high-affinity agonists. LXR activation exerts a combination of metabolic and anti-inflammatory actions that result in the modulation of immune responses and in the amelioration of inflammatory disorders. In addition, LXR agonists modulate the metabolism of infected cells and limit the infectivity and/or growth of several pathogens. This review gives an overview of the recent advances in understanding the complexity of the mechanisms through which the LXR pathway controls inflammation and host-cell pathogen interaction.


Subject(s)
Liver X Receptors/immunology , Animals , Host-Pathogen Interactions , Humans , Infections/immunology , Inflammation/immunology
2.
Cells ; 9(1)2020 01 16.
Article in English | MEDLINE | ID: mdl-31963337

ABSTRACT

CD38 is a multifunctional protein widely expressed in cells from the immune system and as a soluble form in biological fluids. CD38 expression is up-regulated by an array of inflammatory mediators, and it is frequently used as a cell activation marker. Studies in animal models indicate that CD38 functional expression confers protection against infection by several bacterial and parasitic pathogens. In addition, infectious complications are associated with anti-CD38 immunotherapy. Although CD38 displays receptor and enzymatic activities that contribute to the establishment of an effective immune response, recent work raises the possibility that CD38 might also enhance the immunosuppressive potential of regulatory leukocytes. This review integrates the current knowledge on the diversity of functions mediated by CD38 in the host defense to infection.


Subject(s)
ADP-ribosyl Cyclase 1/metabolism , Infections/immunology , ADP-ribosyl Cyclase 1/deficiency , Animals , Disease Susceptibility , Humans , Immunotherapy , Infections/pathology , Infections/therapy , Phagocytosis , Phenotype
3.
PLoS Genet ; 15(9): e1008399, 2019 09.
Article in English | MEDLINE | ID: mdl-31527905

ABSTRACT

Antimicrobial resistance (AMR) is currently one of the most important challenges to the treatment of bacterial infections. A critical issue to combat AMR is to restrict its spread. In several instances, bacterial plasmids are involved in the global spread of AMR. Plasmids belonging to the incompatibility group (Inc)HI are widespread in Enterobacteriaceae and most of them express multiple antibiotic resistance determinants. They play a relevant role in the recent spread of colistin resistance. We present in this report novel findings regarding IncHI plasmid conjugation. Conjugative transfer in liquid medium of an IncHI plasmid requires expression of a plasmid-encoded, large-molecular-mass protein that contains an Ig-like domain. The protein, termed RSP, is encoded by a gene (ORF R0009) that maps in the Tra2 region of the IncHI1 R27 plasmid. The RSP protein is exported outside the cell by using the plasmid-encoded type IV secretion system that is also used for its transmission to new cells. Expression of the protein reduces cell motility and enables plasmid conjugation. Flagella are one of the cellular targets of the RSP protein. The RSP protein is required for a high rate of plasmid transfer in both flagellated and nonflagellated Salmonella cells. This effect suggests that RSP interacts with other cellular structures as well as with flagella. These unidentified interactions must facilitate mating pair formation and, hence, facilitate IncHI plasmid conjugation. Due to its location on the outer surfaces of the bacterial cell, targeting the RSP protein could be a means of controlling IncHI plasmid conjugation in natural environments or of combatting infections caused by AMR enterobacteria that harbor IncHI plasmids.


Subject(s)
Conjugation, Genetic/genetics , Immunoglobulin Domains/genetics , R Factors/genetics , Amino Acid Sequence , Anti-Bacterial Agents/pharmacology , Bacteria/genetics , Bacterial Proteins/genetics , Drug Resistance, Microbial/genetics , Immunoglobulin Domains/physiology , Plasmids/genetics , Salmonella/genetics
4.
Methods Mol Biol ; 1951: 135-141, 2019.
Article in English | MEDLINE | ID: mdl-30825149

ABSTRACT

Macrophages are phagocytic cells that actively engulf and kill microorganisms within a specialized phagolysosomal system. Several pathogenic bacteria, however, actively co-opt host mechanisms and escape from microbial digestion to establish intracellular replication within macrophages. This chapter highlights detailed protocols to measure the effects of the LXR pathway on bacterial infection of murine bone marrow-derived macrophages.


Subject(s)
Bacterial Infections/metabolism , Liver X Receptors/agonists , Liver X Receptors/metabolism , Macrophages/drug effects , Macrophages/metabolism , Animals , Bacterial Infections/microbiology , Biomarkers , Flow Cytometry , Immunophenotyping , Mice , Microscopy, Confocal , Orphan Nuclear Receptors/agonists , Orphan Nuclear Receptors/metabolism
5.
Cancer Immunol Immunother ; 68(4): 673-685, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30569204

ABSTRACT

Many pathogens, ranging from viruses to multicellular parasites, promote expansion of MDSCs, which are myeloid cells that exhibit immunosuppressive features. The roles of MDSCs in infection depend on the class and virulence mechanisms of the pathogen, the stage of the disease, and the pathology associated with the infection. This work compiles evidence supported by functional assays on the roles of different subsets of MDSCs in acute and chronic infections, including pathogen-associated malignancies, and discusses strategies to modulate MDSC dynamics to benefit the host.


Subject(s)
Communicable Diseases/etiology , Communicable Diseases/metabolism , Myeloid-Derived Suppressor Cells/immunology , Myeloid-Derived Suppressor Cells/metabolism , Acute Disease , Animals , Biomarkers , Chronic Disease , Communicable Diseases/drug therapy , Disease Susceptibility , Host-Pathogen Interactions/immunology , Humans , Immunomodulation , Molecular Targeted Therapy , Myeloid-Derived Suppressor Cells/drug effects
6.
Sci Rep ; 8(1): 6535, 2018 04 25.
Article in English | MEDLINE | ID: mdl-29695842

ABSTRACT

Metal limitation is a common situation during infection and can have profound effects on the pathogen's success. In this report, we examine the role of zinc limitation in the expression of a virulence factor in uropathogenic Escherichia coli. The pyelonephritis isolate J96 carries two hlyCABD operons that encode the RTX toxin α-hemolysin. While the coding regions of both operons are largely conserved, the upstream sequences, including the promoters, are unrelated. We show here that the two hlyCABD operons are differently regulated. The hly II operon is efficiently silenced in the presence of zinc and highly expressed when zinc is limited. In contrast, the hly I operon does not respond to zinc limitation. Genetic studies reveal that zinc-responsive regulation of the hly II operon is controlled by the Zur metalloregulatory protein. A Zur binding site was identified in the promoter sequence of the hly II operon, and we observe direct binding of Zur to this promoter region. Moreover, we find that Zur regulation of the hly II operon modulates the ability of E. coli J96 to induce a cytotoxic response in host cell lines in culture. Our report constitutes the first description of the involvement of the zinc-sensing protein Zur in directly modulating the expression of a virulence factor in bacteria.


Subject(s)
Hemolysin Proteins/genetics , Uropathogenic Escherichia coli/genetics , Virulence Factors/genetics , Virulence/genetics , Zinc/metabolism , Bacterial Proteins/genetics , Escherichia coli Infections/microbiology , Escherichia coli Proteins/genetics , Gene Expression Regulation, Bacterial/genetics , Operon/genetics , Promoter Regions, Genetic/genetics , Pyelonephritis/genetics
7.
Cell Rep ; 18(5): 1241-1255, 2017 01 31.
Article in English | MEDLINE | ID: mdl-28147278

ABSTRACT

Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of non-opsonized Salmonella to infect macrophages. Remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bone-marrow-derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway.


Subject(s)
Liver X Receptors/metabolism , Macrophages/metabolism , NAD/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Salmonella Infections/metabolism , Salmonella typhimurium/pathogenicity , ADP-ribosyl Cyclase 1/metabolism , Actin Cytoskeleton/metabolism , Animals , COS Cells , Cell Line , Chlorocebus aethiops , Female , Male , Mice , RAW 264.7 Cells
8.
Immunotherapy ; 8(5): 613-32, 2016 05.
Article in English | MEDLINE | ID: mdl-27140413

ABSTRACT

Immunotherapies are achieving clinical success for the treatment of many cancers. However, it has taken a long time to exploit the potential of the immune system for the treatment of human cancers. We cannot forget that this has been the consequence of very extensive work in basic research in preclinical models and in human patients. Thus, it is rather hard to compile all of it while giving a comprehensive view on this subject. Here we have attempted to give an overall perspective in immunotherapy of melanoma. A brief overview on current therapies is provided, followed by adoptive cell therapies. Gene engineering strategies to improve these therapies are also explained, finishing with therapies based on interference with immune checkpoint pathways.


Subject(s)
Immunotherapy, Adoptive , Immunotherapy/methods , Melanoma/therapy , Animals , Disease Models, Animal , Genetic Engineering , Humans , Immunotherapy/trends , Lymphocyte Activation , Melanoma/immunology , Molecular Targeted Therapy , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...